Clinical research study

LGMD2A/R1 Patient Enrollment Underway for C3-Sponsored Natural History Study

The GRASP-LGMD consortium is currently recruiting for a natural history study for individuals with mutations in CAPN3 (calpain 3). This study will inform the design of future therapeutic trials and a better understanding of the disease. Participants can now enroll at

C3 is Connecting Patients to Clinical Studies

Coalition to Cure Calpain 3 is a vital hub connecting patients with limb-girdle muscular dystrophy type 2A (LGMD2A/R1) to clinical studies. In celebration of ten years of progress in our mission to fund research for a cure and raise global awareness, we

Patient Recruitment Underway for C3-Sponsored Natural History Study

The GRASP-LGMD is currently recruiting for a natural history study for individuals with mutations in CAPN3 (calpain 3). This study will inform the design of future therapeutic trials and a better understanding of the disease. Participants can now enroll at Virginia

May 20 is Clinical Trials Day

Clinical Trials Day occurs every year on May 20 to recognize the people who conduct clinical research trials and to provide an opportunity to raise awareness of clinical trials. This date was chosen to commemorate the day that James Lind

New resource to learn about clinical research opportunities for LGMD2A

Are you or a family member with LGMD2A interested in participating in clinical research studies or trials? Click here to view C3’s new Clinical Research Opportunity Resource Center to learn more about clinical research and current opportunities to participate. This

University of Florida College of Medicine Study Recruiting LGMD2A Patients Living in the Southeast U.S. and Texas

Individuals with LGMD2A, a form of calpainopathy, are being sought for a Magnetic Resonance Imaging (MRI) and Spectroscopy (MRS) study. Please direct any questions related to this study, including participation guidelines and aims, to Dr. Glenn Walter, University of Florida

Individuals with LGMD are sought for clinical trial evaluating the safety and efficacy of oral weekly glucocorticoid steroids

A clinical trial is being initiated at Northwestern University in Chicago, Illinois. The aim of the study is to test the safety and efficacy of once weekly dosing of oral prednisone, a glucocorticoid steroid. Both ambulatory and nonambulatory patients

Patients Sought for C3-funded Clinical Endpoints Study

Coalition to Cure Calpain 3 (C3) is pleased to announce that a research grant has been awarded to Dr. Nicholas Johnson, Associate Professor & Vice Chair of Research, Virginia Commonwealth University. The project is titled “Defining Clinical Endpoints in LGMD.”